<DOC>
	<DOC>NCT00991718</DOC>
	<brief_summary>This is an open-label, Phase I, single-center, single-dose administration study to determine the absolute bioavailability, clearance, and volume of distribution of GDC-0449 (Part A) and to determine the routes of excretion and extent of metabolism of GDC-0449 (Part B). Parts A and B will be conducted sequentially, with â‰¥ 7 days between dosing the sixth subject in Part A and dosing the first subject in Part B. In each part, 6 healthy female subjects of non-childbearing potential, between 18 and 65 years of age (inclusive), will be dosed.</brief_summary>
	<brief_title>A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Female Nonchildbearing potential Body mass index (BMI) between 18 and 32 kg/m^2, inclusive In good health, determined by no clinically significant findings on physical examination, medical history, 12lead ECG, and vital signs Negative test for drugs of abuse at screening (does not include alcohol) and at admission to the clinical research facility (does include alcohol) Exclusion Criteria History or clinical manifestations of clinically significant metabolic, hepatic, renal, hematologic, pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urologic, neurologic, inflammatory, or psychiatric disorders, or cancer History of symptomatic hypotension, idiopathic orthostatic hypotension, or other autonomousfailure syndromes History of severe physical injury, direct impact trauma, or neurological trauma within 6 months prior to Day 1 History of stomach or intestinal surgery, stomach disease, or resection that would potentially alter absorption and/or excretion of orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy are allowed) History of alcoholism, drug abuse, or drug addiction (including soft drugs like cannabis products) Use of any prescription medications/products, including known enzymeinducing/inhibiting agents, overthecounter medication, or other nonprescription preparations (including supplements, vitamins, minerals, phytotherapeutic/herbal/ plantderived preparations, the tryptophans, and St. John's wort or other hypericum perforatumcontaining substance) within 2 weeks prior to Day 1, with the exception of hormonereplacement therapy Participation in any other investigational drug study in which receipt of an investigational study drug occurred within 60 days prior to Day 1 or within 5 times the elimination halflife of the respective drug; participation in a trial involving administration of ^1^4Cradiolabeled compound(s) within 6 months prior to Day 1; participation in more than two other drug trials within 1 year prior to Day 1 Receipt of any vaccination or immunization within 1 month prior to Day 1 Use of any nicotinecontaining or nicotinereplacement products within 6 months prior to Day 1 Consumption of alcohol or methylxanthinecontaining beverages or food Receipt of blood products within 2 months prior to Day 1 Donation of &gt; 100 mL of blood within 60 days prior to Day 1; donation of &gt; 1.0 litres of blood within 10 months prior to Day 1 Irregular defecation pattern, i.e., less than once per 2 days within 6 months prior to Day 1; acute constipation problems within 3 weeks prior to Day 1 (Part B subjects only) Poor peripheral venous access</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>GDC0449</keyword>
</DOC>